Skip to main content

Table 1 Baseline demographics and clinical characteristics in axial spondyloarthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis populations (randomized sets, observed cases)a

From: Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis

  axSpA (n = 325) AS (n = 178) nr-axSpA (n = 147)
Demographic characteristics  
  Age, yr 39.6 ± 11.9 41.5 ± 11.6 37.4 ± 11.8
  Sex, % male 61.5 72.5 48.3
  Race, % white 90.2 89.3 91.2
Disease characteristics  
  Time from axSpA diagnosisb (yr), median (min–max) 3.9 (0.0 to 37.9) 5.5 (0.2 to 37.9) 2.5 (0.0 to 32.2)
  Symptom duration (yr), median (min–max) 7.7 (0.3 to 50.9) 9.1 (0.3 to 50.9) 5.5 (0.3 to 41.5)
  CRPc (mg/L), median (min–max) 13.9 (0.1 to 174.8) 14.3 (0.1 to 174.8) 11.9 (0.1 to 156.2)
  Positive for HLA-B27, n (%) 255 (78.5) 145 (81.5) 110 (74.8)
  BASDAI 6.5 ± 1.6 6.4 ± 1.6 6.5 ± 1.5
  BASFI 5.4 ± 2.2 5.7 ± 2.2 4.9 ± 2.3
  BASMI 3.8 ± 1.7 4.4 ± 1.7 3.2 ± 1.5
  ASDAS 3.8 ± 1.0 3.9 ± 0.9 3.7 ± 1.0
  Total spine paind 7.0 ± 1.9 7.1 ± 1.9 7.0 ± 1.9
  Nocturnal spine paind 6.9 ± 2.3 6.9 ± 2.2 6.9 ± 2.5
Prior TNF inhibitor exposure, % 16.0 20.2 10.9
Health-related quality of life
  Fatigue NRSd 6.7 ± 1.9 6.6 ± 2.0 6.7 ± 1.8
  SF-36 MCSd 40.5 ± 12.1 40.9 ± 12.0 40.0 ± 12.3
  SF-36 PCSd 32.5 ± 7.5 32.0 ± 7.3 33.1 ± 7.8
  ASQoLd 11.8 ± 4.3 11.8 ± 4.3 11.7 ± 4.3
  EQ-5D VAS 48.3 ± 19.4 47.3 ± 18.5 49.4 ± 20.4
  1. aASDAS: Ankylosing spondylitis disease activity scale; ASQoL: Ankylosing spondylitis quality of life; axSpA, Axial spondyloarthritis; BASDAI: Bath ankylosing spondylitis disease activity index; BASFI: Bath ankylosing spondylitis functional index; BASMI: Bath ankylosing spondylitis metrology index; CRP: C-reactive protein; EQ-5D: EuroQoL 5 dimensions; HLA: Human leukocyte antigen; MCS: Mental component summary; nr-axSpA, Nonradiographic axial spondyloarthritis; NRS: Numerical rating scale; PCS: Physical component summary; SF-36: Short form 36 item; TNF: Tumor necrosis factor; VAS: Visual analogue scale. bFrom the start date of the primary disease. cNormal range of CRP <8.0 mg/L. dIn full analysis set population: n = 324 axSpA, 178 AS, 146 nr-axSpA. Except where indicated otherwise, values are the mean ± SD. There were no significant differences between treatment groups at baseline.